CTI BioPharma Release: Analysis Of Pivotal Phase 3 Patient Outcomes By Subgroups Shows Treatment With Pacritinib Resulted In Consistent Rates Of Reduction In Spleen Volume And Symptom Burden

Press/Media: Press / Media

PeriodDec 7 2015

Media coverage

1

Media coverage

  • TitleCTI BioPharma Release: Analysis Of Pivotal Phase 3 Patient Outcomes By Subgroups Shows Treatment With Pacritinib Resulted In Consistent Rates Of Reduction In Spleen Volume And Symptom Burden
    Media name/outletBioSpace
    CountryUnited States
    Date12/7/15
    PersonsRuben Mesa